Pharma News, 2017

SAN DIEGO, June 15, 2017 (GLOBE NEWSWIRE) --  Adamis Pharmaceuticals Corporation (NASDAQ.

Novartis and Verily have helped Medicxi raise $300 million (€268 million) to invest in late-stage drug developers.

In research that should be essential reading for anyone involved in attempts to reduce US drug prices, it has been found that more than 40% of the money spent by consumers on pharmaceuticals goes ...

A bipartisan group of state attorneys general announced on Thursday that they are jointly investigating the marketing and sales practices of drug companies that manufacture opioid painkillers at the c...

Earlier this month, industry watchers questioned who could swallow the reportedly on-the-block Tesaro and its $7.

Invokana is a next-generation SGLT-2 inhibitor that has the opportunity to slowly push traditional DPP-4 inhibitors like Merck's (NYSE.

Researchers have found a way to increase the effectiveness of a widely used cancer drug while decreasing the risk of heart-damaging side effects, according to a new study by researchers from The Unive...

Diversified healthcare company Johnson & Johnson said on Wednesday its experimental flu drug significantly reduced the presence of the virus in patients with a type of influenza in a mid-stage stu...

Sanofi announced plans to invest 600 million euros ($673 million) annually over the next two to three years in the field of biologics production, an area of strong growth potential.

On June 6, 2017, the U.

Research published in Nature magazine’s Scientific Reports offers hope that a new combination therapy could represent a safer and more effective option for cancer patients.

The Association for Accessible Medicines (AAM) says that generic drugs saved the US healthcare system $253 billion last year, and a total of $1.